EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

Shao Xie,1,2,# Fan Wei,1,3,# Yi-ming Sun,1 Ying-lei Gao,1 Lu-lu Pan,3,4 Min-jia Tan,4 Shu-dong Wang,5 Jian Ding1 and Yi Chen1

1Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2Key Laboratory of Breast Cancer, and Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; 3University of Chinese Academy of Sciences, Beijing, China; 4Chemical Proteomics Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica and Chinese Academy of Sciences, Shanghai, China and 5Centre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, University of South Australia Cancer Research Institute, Adelaide, Australia

#SX and FW are co-first authors.

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.222935

Received: March 26, 2019.
Accepted: July 5, 2019.
Pre-published: July 9, 2019.
Correspondence: YI CHEN - ychen@simm.ac.cn
JIAN DING - jding@simm.ac.cn
Supplementary Material

Supplementary Methods

Chemicals and antibodies

CDKI-73 was kindly provided by Professor Shudong Wang (University of South Australia, Adelaide, Australia). Flavopiridol HCl (S2679), EZP6438 (S7128), GSK126 (S7061), SNS-032 (S1145), AT7519 (S1524), and Dinaciclib (S2768) were purchased from Selleck Chemicals (Houston, TX, USA). The primary antibodies: p-RNA Pol II ser2 (ab70324), UTX (ab84190) (Abcam, Cambridge, UK); PARP (9542S), XIAP (2042S), MCL1 (4572S), β-Tubulin (2146S), BCL-XL (2764S), GAPDH (5174S), H3K79me3 (4260S), H3K36me3 (9763S), H3K9me2 (4658S), H3K27me1 (7693S), H3K27me2 (9728S), H3K27me3 (9733S), Histone H3 (4499S), β-Actin (4970S), EZH2 (5246S), JMJD3 (3457S), CDK9 (2316S), γ-H2AX (9718S) (Cell Signaling Technology, MA, USA); RNA Pol II (sc-56767), SUZ12 (sc-271325), EED (sc-293203) (Santa Cruz Biotechnology, CA, USA).

Cell culture

The lymphoma cells Pfeiffer, SU-DHL-6, breast cancer cells MCF-7, colorectal cancer cells SW620, gastric cancer cells SGC-7901, and embryonic kidney cells HEK293T were purchased from ATCC (Manassas, VA, USA). The lymphoma cells Karpas-299, HT, RL, DB, SU-DHL-5, Will-1, Will-2, U2932, Karpas-1106P, Karpas-422, SU-DHL-4, SU-DHL-8, WSU-DLCL2, and breast cancer cells MDA-MB-453 were purchased from DSMZ (Brunswick, Germany). All these cells were maintained following the providers’ instructions.

Proliferation and apoptosis assays

The cytotoxicity of CDKI-73 alone and the combination treatment were investigated using a panel of human DLBCL cell lines and solid tumor cells. Cells plated in 96-well plates were treated with gradient concentrations of the compounds at 37°C for appropriate time. A cell proliferation assay was carried out using resazurin (Sigma Aldrich, Darmstadt, Germany) for DLBCL cells and
Sulforhodamine B (Sigma Aldrich) for solid tumor cells. The percent of cells in apoptosis was determined using Annexin V-FITC/PI double staining kit (Vazyme Biotech, Nanjing, China) and analyzed using BD FlowJo software.

**Comet assay**

Slides were pre-coated with 1% normal melting point agarose. About $3 \times 10^4$ cells were mixed with 70 μl of 1% low melting point agarose in phosphate-buffered saline (PBS), and rapidly spread onto the pre-coated slides. The slides were immediately placed in cold lysis buffer containing 2.5 M NaCl, 100 mM EDTA, 10 mM Tris (pH 7.5), 1% Triton X-100, 1% INCI, and 10% DMSO at 4°C for 1–3 h. The slides were then placed in the electrophoresis solution for 20 min to facilitate DNA unwinding before electrophoresis was conducted for 20 min at 25 V and 300 mA. After electrophoresis, the slides were washed with PBS and then stained with DAPI. The individual cells were viewed using an Olympus BX51 UV fluorescence microscope (Olympus, Japan).

**Colony formation assay**

Cells were seeded into 6-well plates at a concentration of 500-1000 cells per well. After 24 h, cells were treated with indicated compounds for about 2 weeks. Colonies were fixed with fixation solution (10% methanol + 10% acetic acid) at room temperature for 15 min and then stained with a solution of 1% crystal violet in methanol for 15 min.

**RNA isolation and Real-Time PCR analysis**

RNA from cell lines was isolated using Trizol extraction (Thermo Fisher Scientific). cDNA was prepared using HiScript II 1st Strand cDNA Synthesis Kit (+gDNA wiper) (Vazyme Biotech). RT-qPCR was performed following the instruction for ChamQ SYBR qPCR Master Mix (Vazyme Biotech) with V7 Real-Time PCR system (Thermo Fisher Scientific). Expressed values relative to control were calculated using the DDCT method. β-actin was used as a housekeeping gene for
normalization. Results were represented as fold expression. The sequences of primers used for qPCR analysis were listed below.

| Gene       | Forward primer sequence | Reverse primer sequence |
|------------|-------------------------|-------------------------|
| Mcl-1      | 5'-AAAAGCAAGTGCCAAGAGGA-3' | 5'-TTAATGAAATTGGCGGGTAA-3' |
| XIAP       | 5'-TGGCATTCCAGATTTGGGC-3' | 5'-TAGGAATTGTCACCCTTTTCGC-3 |
| GAPDH      | 5'-GAAGGTGAAGGTCGGAGT-3'  | 5'-GAAGATTTGATGGGATTTTC-3' |
| β-Actin    | 5'-GCGGAAGATGACCCAGATC-3' | 5'-GGATAGCACAGCTGGATAG-3' |
| GATA4      | 5'-GCGGAAAGAGGAGGCATCCAA-3' | 5'-CTTGTTGGAGAGGCTTCAAGG-3' |
| CDKN2A     | 5'-CGACTCTGGAGGACGAAGTT-3' | 5'-CCAGGAACGGCTCCCCTTTTT-3' |
| HOXC8      | 5'-GGGGAGACGGAGAAACAGTG-3' | 5'-GTGTGGTGAGAGACAGACCCG-3' |
| TNFRSF21   | 5'-GAGAGGGAGTTGCTTCTT-3'  | 5'-CAACATCGTTTCTCCGGTGC-3' |
| EZH2       | 5'-TTGGTGCGGTCTTTATCCGC-3' | 5'-GGCCCACTCTCCTCTGAAAT-3' |
| UTX        | 5'-CGTGTGATCAGCAAGAA-3'   | 5'-CACCCCACTTACCTTCAGGA-3' |
| JMJD3      | 5'-GGTTCCAATGAGACAGGGCA-3' | 5'-GATAAGATGGCCCGCTACCC-3' |
Supplementary Figure 1. CDKI-73 increases H3K27me3 through CDK9 inhibition. (A) Methylated histone level in Karpas-422, MCF-7, SGC-7901, MDA-MB-453, and SW620 cells after exposure to CDKI-73/Flavopiridol for 24 h. (B) The influence of CDK9 knock down on the protein level of H3K27me3 in Pfeiffer. (C, D) The H3K27ac level in Karpas-422 cells after CDKI-73 treatment for 24 h and CDK9 knock down.

Supplementary Figure 2. Transcriptional repression contributed to H3K27me3 elevation via CDK9 inhibition. (A) Protein levels of H3K27-related methyltransferases and demethylases in SU-DHL-4 cells after exploring to CDKI-73 or Flavopiridol. (B) Quantitative assessment of immunoprecipitation (IP) for Phosphor-Ser/Thr of EZH2 in SU-DHL-4 when pretreated with 0.1 μM CDKI-73 for 12 h. EZH2 was used as a loading control. C: CDKI-73. All data are representative of at least three independent experiments.

Supplementary Figure 3. CDK9 inhibition synergies with EZH2 inhibition. (A) Impact of CDK9 knock down on the sensitivity of Pfeiffer cells to EPZ6438. Western blotting analysis of CDK9 depletion. (B) Average CI values of Pfeiffer, Karpass-422, SGC-7901, MCF-7 and SW620 cell lines for combination of different CDK9 inhibitors and EPZ6438/GSK126. Cells were treated as Figure 4D mentioned. (C) Impact of CDK9 knock down on the proliferation of EZH2 low expressed MCF-7 cells. Western blotting analysis of CDK9 and EZH2 depletion. All data are representative of at least three independent experiments.
Supplementary Table S1. Normalized CDK1-73/DMSO ratios in Mass Spectrometry

| Sites            | Ratio | Sites            | Ratio | Sites            | Ratio |
|------------------|-------|------------------|-------|------------------|-------|
| H3K9ac           | 0.73  | H3K36me1         | 0.90  | H2AK5ac          | 0.61  |
| H3K9me3          | 1.03  | H3K56ac          | 1.07  | H2AK7ac          | 1.06  |
| H3K9me2          | 0.67  | H3K79ac          | 0.97  | H2AK9ac          | 0.61  |
| H3K9me1          | 0.99  | H3K79me2         | 0.98  | H2AK11ac         | 1.02  |
| H3K14ac          | 0.70  | H3K79me1         | 1.11  | H4K5ac           | 0.89  |
| H3K18ac          | 1.05  | H2BK16ac         | 0.64  | H4K8ac           | 0.83  |
| H3K18me1         | 1.36  | H2BK20ac         | 0.85  | H4K12ac          | 0.73  |
| H3K23ac          | 1.20  | H2BK23ac         | 0.65  | H4K16ac          | 0.97  |
| H3K27ac          | 0.42  | H2BK34ac         | 1.10  | H4K20me2         | 0.90  |
| H3K27me3         | 1.29  | H2BK116ac        | 1.13  | H4K20me          | 0.72  |
| H3K27me2         | 0.67  | H2BK120ac        | 1.16  | H4K31ac          | 0.94  |
| H3K27me1         | 0.68  | H2AK4ac          | 1.07  | H4K77ac          | 1.00  |

Supplementary Table S2. Plasmids in stable transfection

| Gene   | Plasmid number |
|--------|----------------|
| CDK9-1 | TRCN0000000494 |
| CDK9-2 | TRCN0000000495 |

All the plasmids were purchased from Sigma-Aldrich

Supplementary Table S3. siRNA sequences in RNA interference

| Gene   | siRNA sequence (sense) |
|--------|------------------------|
| CDK9-1 | 5'-UAGGGGACAUGAAGGCUGCUAA-3' |
| CDK9-8 | 5'-GGGCAUUUGAGUUUAUAUC-3' |
| CDK9-103 | 5'-GGUGCUAGUGAAAACGAGTT-3' |
| CDK1   | 5'-CGGGAAAUUUCUCUAUA-3' |
| CDK2   | 5'-GGAGCUUGUUAUCGCCAAAU-3' |
| CDK4-1 | 5'-GGGCAAUCUUUGCCUUUAU-3' |
| CDK4-2 | 5'-CCAGGACCUAAGGACAUAU-3' |
| CDK7-1 | 5'-GCCUACAUGUGUGAUGACUC-3' |
| CDK7-2 | 5'-GAGUUUUCUGGAAUACC-3' |